ArriVent BioPharma
ArriVent is a Pennsylvania company developing furmonertinib, an EGFR inhibitor approved in China, for EGFR exon 20 insertion and other uncommon EGFR-mutant lung cancers in global trials.
Overview
ArriVent BioPharma, based in Newtown Square, Pennsylvania and listed on Nasdaq since 2024, licenses medicines approved in China for development elsewhere. Its lead is furmonertinib (firmonertinib), a third-generation EGFR inhibitor from Allist Pharmaceuticals that is approved in China for EGFR-mutant non-small-cell lung cancer; ArriVent runs the global phase 3 FURVENT trial in EGFR exon 20 insertion mutations, where it holds FDA breakthrough designation. It appears on OnCo as a lead sponsor of phase 3 cancer trials on ClinicalTrials.gov.
Scorecard
All companies- approved products +6
- targets +2
- modalities +2
- regions +1
- registry trials +15
Similar pages
not linked directly; found by shared links- CompanySTCube
Shares Non-small-cell lung cancer and the tag ctgov-sponsor.
- CompanyCivaTech Oncology
Shares Non-small-cell lung cancer and the tag ctgov-sponsor.
- CompanyKrystal Biotech
Shares Non-small-cell lung cancer and the tag ctgov-sponsor.
- CompanymAbxience Research S.L.
Shares Non-small-cell lung cancer and the tag ctgov-sponsor.
- CompanyCatalYm
Shares Non-small-cell lung cancer and the tag ctgov-sponsor.
- CompanyCelltrion
Shares Non-small-cell lung cancer and the tag ctgov-sponsor.
- CompanyGenprex
Shares Non-small-cell lung cancer and the tag ctgov-sponsor.
- CompanyShanghai Fosun Pharmaceutical Industrial Development
Shares Non-small-cell lung cancer and the tag ctgov-sponsor.